SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hejing Huang, Lili Zhou, Lihui Peng, Weijun Fu, Chunyang Zhang, Jian Hou, Bortezomib–thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials, Leukemia Research, 2014, 38, 9, 1048

    CrossRef

  2. 2
    Temenushka Boneva, Diana Brazma, Katya Gancheva, Julie Howard-Reeves, Julian Raynov, Colin Grace, Elisabeth P Nacheva, Can genome array screening replace FISH as a front-line test in multiple myeloma?, Genes, Chromosomes and Cancer, 2014, 53, 8
  3. 3
    Isabella C. Glitza, Gary Lu, Rupin Shah, Qaiser Bashir, Nina Shah, Richard E. Champlin, Jatin Shah, Robert Z. Orlowski, Muzaffar H. Qazilbash, Chromosome 8q24.1/c-MYCabnormality: a marker for high-risk myeloma, Leukemia & Lymphoma, 2014, 1

    CrossRef

  4. 4
    Maximilian Merz, Leonille Schweizer, Modar Kentar, Till Schneider, Hartmut Goldschmidt, Jens Hillengass, Extramedullary relapse after accidental head injury in a patient with multiple myeloma, Annals of Hematology, 2014,

    CrossRef

  5. 5
    N I Herath, N Rocques, A Garancher, A Eychène, C Pouponnot, GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target, Blood Cancer Journal, 2014, 4, 1, e175

    CrossRef

  6. 6
    Adewale Fawole, Rafat Abonour, Michael Stender, Seerin Shatavi, Susanna Gaikazian, Joseph Anderson, Ishmael Jaiyesimi, Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?, Leukemia & Lymphoma, 2014, 1

    CrossRef

  7. 7
    Melissa Alsina, Pamela S. Becker, Xiaobo Zhong, Alexia Adams, Parameswaran Hari, Scott Rowley, Edward A. Stadtmauer, David H. Vesole, Brent Logan, Daniel Weisdorf, Muzaffar Qazilbash, Leslie L. Popplewell, Brian McClune, William Bensinger, Marcie Riches, Sergio A. Giralt, Marcelo C. Pasquini, Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, 2014, 20, 8, 1183

    CrossRef

  8. 8
    Nikhil Patkar, P. G. Subramanian, Prashant Deshpande, Kiran Ghodke, Prashant Tembhare, Russel Mascarenhas, Aditi Muranjan, Shruti Chaudhary, Bhausaheb Bagal, Sumeet Gujral, Manju Sengar, Hari Menon, MYD88mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart, Leukemia & Lymphoma, 2014, 1

    CrossRef

  9. 9
    Wenting Zhang, Woo Y. Lee, David S. Siegel, Peter Tolias, Jenny Zilberberg, Patient-Specific 3D Microfluidic Tissue Model for Multiple Myeloma, Tissue Engineering Part C: Methods, 2014, 20, 8, 663

    CrossRef

  10. 10
    G W Gordon, J Monge, M B Channon, Q Wu, J L Skulan, A D Anbar, R Fonseca, Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition, Leukemia, 2014,

    CrossRef

  11. 11
    Vishal Bhatnagar, Ashraf Badros, The role of clonal evolution in smoldering multiple myeloma, Leukemia & Lymphoma, 2014, 55, 2, 464

    CrossRef

  12. 12
    K R Carson, M L Bates, M H Tomasson, The skinny on obesity and plasma cell myeloma: a review of the literature, Bone Marrow Transplantation, 2014, 49, 8, 1009

    CrossRef

  13. 13
    Eirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, Maria Kotsopoulou, Sossana Delimpasi, Marie-Christine Kyrtsonis, Argiris Symeonidis, Nikos Giannakoulas, Aikaterini Stefanoudaki, Dimitrios Christoulas, Christina Chatziaggelidou, Vassiliki Gastari, Nikos Spyridis, Evgenia Verrou, Pavlina Konstantinidou, Kostas Zervas, Meletios A. Dimopoulos, Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group, American Journal of Hematology, 2014, 89, 2
  14. 14
    S V Rajkumar, V Gupta, R Fonseca, A Dispenzieri, W I Gonsalves, D Larson, R P Ketterling, J A Lust, R A Kyle, S K Kumar, Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma, Leukemia, 2013, 27, 8, 1738

    CrossRef

  15. 15
    Chiara Cerrato, Antonio Palumbo, Initial Treatment of Nontransplant Patients With Multiple Myeloma, Seminars in Oncology, 2013, 40, 5, 577

    CrossRef

  16. You have free access to this content16
    S. Vincent Rajkumar, IV. Initial treatment of multiple myeloma, Hematological Oncology, 2013, 31, S1
  17. 17
    Sanjeev Sethi, S. Vincent Rajkumar, Monoclonal Gammopathy–Associated Proliferative Glomerulonephritis, Mayo Clinic Proceedings, 2013, 88, 11, 1284

    CrossRef

  18. 18
    Alexandra J. Greenberg, Denise K. Walters, Shaji K. Kumar, S. Vincent Rajkumar, Diane F. Jelinek, Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels, European Journal of Haematology, 2013, 91, 6
  19. 19
    Dominik Dytfeld, Translational research w szpiczaku plazmocytowym polską szansą na przyspieszenie?, Acta Haematologica Polonica, 2013, 44, 3, 196

    CrossRef

  20. 20
    A. Hochhaus, P. La Rosée, L.-O. Mügge, H.G. Sayer, S. Scholl, Zielgerichtete Therapien bei hämatologischen Erkrankungen, Der Onkologe, 2013, 19, 10, 835

    CrossRef